Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
NCT ID: NCT01015183
Last Updated: 2011-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
60 participants
INTERVENTIONAL
2009-11-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of N-Acetylcysteine Mouthwash in Prevention of Mucositis in HSCT Patients
NCT07325383
Oral Selenium Therapy for the Prevention of Mucositis
NCT01432873
Oral Hygiene Regimen in Patients on HCT
NCT02662374
N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.
NCT04756622
Oral Zinc Therapy for the Prevention of Mucositis
NCT00449592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Received Zinc Sulfate
Zinc Sulfate
Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
Control
Control group
Placebo
Placebo: as the same of intervention group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zinc Sulfate
Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
Placebo
Placebo: as the same of intervention group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tehran University of Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Molouk Hadjibabaie, PhD
Role: PRINCIPAL_INVESTIGATOR
Hematology-Oncology and SCT Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology-Oncology & SCT Research Center
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HORCSCT-0904
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.